Exploiting Human NK Cells in Tumor Therapy

Paola Vacca¹, Gabriella Pietra²,³, Nicola Tumino¹, Enrico Munari⁴, Maria Cristina Mingari²,⁵ and Lorenzo Moretta¹*

¹ Immunology Research Area, IRCCS Bambino Gesù Pediatric Hospital, Rome, Italy, ² UOC Immunology, IRCCS Ospedale Policlinico San Martino, Genoa, Italy, ³ Department of Experimental Medicine (DIMES), Università di Genova, Genoa, Italy, ⁴ Department of Pathology, IRCCS Sacro Cuore Don Calabria, Negrar, Italy, ⁵ Department of Experimental Medicine (DIMES), Center of Excellence for Biomedical Research, Università di Genova, Genoa, Italy

NK cells play an important role in the innate defenses against tumor growth and metastases. Human NK cell activation and function are regulated by an array of HLA class I-specific inhibitory receptors and activating receptors recognizing ligands expressed de novo on tumor or virus-infected cells. NK cells have been exploited in immunotherapy of cancer, including: (1) the in vivo infusion of IL-2 or IL-15, cytokines inducing activation and proliferation of NK cells that are frequently impaired in cancer patients. Nonetheless, the significant toxicity experienced, primarily with IL-2, limited their use except for combination therapies, e.g., IL-15 with checkpoint inhibitors; (2) the adoptive immunotherapy with cytokine-induced NK cells had effect on some melanoma metastases (lung), while other localizations were not affected; (3) a remarkable evolution of adoptive cell therapy is represented by NK cells engineered with CAR-targeting tumor antigens (CAR-NK). CAR-NK cells complement CAR-T cells as they do not cause GvHD and may be obtained from unrelated donors. Accordingly, CAR-NK cells may represent an “off-the-shelf” tool, readily available for effective tumor therapy; (4) the efficacy of adoptive cell therapy in cancer is also witnessed by the αβ T cell- and B cell-depleted haploidentical HSC transplantation in which the infusion of donor NK cells and γδ T cells, together with HSC, sharply reduces leukemia relapses and infections; (5) a true revolution in tumor therapy is the use of mAbs targeting checkpoint inhibitors including PD-1, CTLA-4, the HLA class I-specific KIR, and NKG2A. Since PD-1 is expressed not only by tumor-associated T cells but also by NK cells, its blocking might unleash NK cells playing a crucial effector role against HLA class I-deficient tumors that are undetectable by T cells.

Keywords: NK cells, inhibitory checkpoints, innate immunity, immunotherapy, anti-tumor therapy

INTRODUCTION

Natural killer (NK) cells play a central role in innate defenses against viruses and tumors. They belong to a family of innate lymphoid cells (ILC) that do not express receptors encoded by rearranged genes. NK cell function is regulated by an array of inhibitory and activating receptors. Inhibitory receptors that play a major role in the control of NK cell function are those specific for HLA-class (Cl)-I molecules. Killer Ig-like receptors (KIRs) recognize allotypic determinants shared by different HLA-CI-I alleles, while CD94/NKG2A is specific for the non-classical HLA-E (1).
fact that NK cell inactivation is required to spare healthy cells implied the existence of activating receptors recognizing ligands on target cells. The prototypes and most important ones in tumor cell detection and killing are NKp46, NKp44, and NKp30, collectively called “natural cytotoxicity receptors” (NCRs) (2). While in an autologous setting all NK cells express one or more inhibitory receptors for self HLA-CI-I, in an allogeneic setting, it may occur that KIRs expressed by a subset of NK cells do not recognize HLA-CI-I alleles on allogeneic cells, and the lack of inhibition may result in killing of target cells (3). NK cells with these characteristics were named “alloreactive” NK cells. Although NK cells display a potent anti-tumor activity and are thought to participate to the control of tumor growth and metastatic spread, the tumor microenvironment may sharply inhibit their effector functions (4, 5). This inhibitory effect is due to the tumor cells themselves as well as to other cells present in the tumor microenvironment and frequently involves both the downregulation of activating surface receptors and the de novo expression of inhibitory checkpoints (primarily PD-1) (6, 7). In this contribution, we will briefly discuss different therapeutic strategies (Table 1), which allow to successfully exploit NK cell-mediated anti-tumor activity as well as novel promising approaches that may offer important new tools in cancer treatment.

**BOOSTING IN VIVO NK CELLS WITH IMMUNE STIMULATORY CYTOKINES**

In cancer patients, NK cells frequently display an impaired function (6, 27). Thus, primary strategies in immunotherapy are aimed to boost in vivo NK cell-mediated antitumor activity. One approach is based on the in vivo administration of cytokines, such as IL-2 and IL-15, that determine NK cell activation, differentiation, and expansion (8, 28–32). IL-2 administration was approved in the 1990s for the treatment of metastatic RCC and melanoma patients (33–35). Two major obstacles in IL-2-based therapy are the dose-associated toxicity (primarily vascular leakage) and the induction of T regulatory (Treg) cell activation and expansion, thus resulting in inhibition of NK cell function (9, 10). Recently, IL-2 variants, with lower affinity for IL-2Rα subunits (highly expressed by Treg cells), have been designed (11, 36, 37). In addition, PEGylated IL-2 (also known as NKTR-214) that binds CD122 (IL-2Rβ), expressed by both T and NK cells, is able to boost preferentially these cells and their anti-tumor responses. This therapeutic treatment is currently under investigation in clinical trials for solid tumors (13). The use of IL-15 may represent a better therapeutic option as it can selectively sustain NK cells without inducing Treg expansion. However, the clinical use of IL-15 is limited because of its short in vivo half-life (38). Notably, IL-15 induces a rapid expansion of memory CD8+ T cells, thus favoring anti-tumor activity. The effect of IL-15 administration combined with checkpoint inhibitors (anti-CTLA-4 and/or anti-PD-1 mAbs) is currently under investigation in patients with cancers refractory to other strategies. To improve the anti-tumor effect of NK cells, ALT-803, an IL-15 superagonist complex, is also being assessed in phase 1 studies either alone (14) or in combination with checkpoint inhibitors (39). An emerging approach is based on bi- or trispecific killer cell engagers (BiKeEs and TriKeEs) binding CD16 or NKG2D on NK cells and tumor antigens, thus favoring the interaction between NK cells and tumor cells. Notably, “TriKeEs” also contain a modified IL-15 linker to improve NK cell survival and proliferation (15, 40, 41). An additional prospect is the use of IL-12, a molecule that enhances cytokine production and cytotoxicity by NK cells (16).

**ADOPTIVE IMMUNOTHERAPY WITH CYTOKINE-INDUCED NK CELLS**

Clinical trials have been attempted since 1980s in which NK cell-containing cell suspensions isolated from patients with metastatic melanomas were expanded in vitro in the presence of IL-2 and infused back into the patients. While a relevant effect was detected in some cases, primarily in metastatic lesions such as lung metastases, other tumor localizations were not affected. These studies were important because they provided the first evidence that such “lymphokine-activated killers” (LAK) could exert their anti-tumor effect also in vivo. Relevant toxicity was mostly related to the concomitant administration of high dosages of IL-2 (17, 18). Evolutions of such pioneering studies, based on adoptive cell therapy, were the use of IL-15 and, recently, the use of NK cells engineered with chimeric antigen receptor (CAR, see below). Although NK cells to be used in adoptive tumor therapy are usually derived from peripheral blood (PB), other sources have also been proposed. For example, the pleural fluid of primary or metastatic tumors contains high numbers of functional NK cells (19), which acquire strong cytotoxicity upon short culture intervals with IL-15 or IL-2 in vitro. Since large volumes of such fluids are routinely discarded, NK cells could be recovered and reinjected systemically or in the pleural cavity after in vitro
culture with IL-15 (8). Such loco-regional treatment might contribute to the control of pleural localizations of the tumor. In general, the infusion of potent effector cells with anti-tumor activity is an important approach in tumor immunotherapy because it may greatly amplify the effect of endogenous cells. The relevance of infusing mature effector cells in cancer patients is also underscored in the αβT- and B-cell-depleted haploidentical hematopoietic stem cell transplantation (HSCT), in which leukemia relapses and infections are sharply reduced as compared to the HSCT setting with “purified” CD34+ cells, thanks to the co-infusion of mature γδT cells and NK cells (see below).

### ROLE OF NK CELLS IN THE THERAPY OF HIGH-RISK LEUKEMIA IN HAPLOIDENTICAL HSCT

HSCT represents the life-saving therapy for acute leukemia poorly responsive to chemotherapy, relapsing, or with adverse cytogenetic characteristics. Unfortunately, it is possible to find a HLA compatible donor only for ~60% of patients (42, 43). Thus, T-depleted haplo-identical HSCT has been developed in an attempt to rescue those patients for whom no alternative therapeutic option is available. Haplo-HSCT is based on the infusion of “megadoses” of purified CD34+ cells extensively depleted of T cells in order to avoid life-threatening GvHD. In this transplantation setting, donor NK cells may express KIR that do not recognize any of the HLA-CI-I alleles of the patient (44, 45). Notably, NK cells are the first donor lymphoid cells detectable in patients’ PB after transplantation. In pediatric patients, this occurs after ~2 weeks. However, such NK cells are represented by relatively immature CD56bright cells, expressing NKG2A but not KIR (KIR expression is required for NK cell alloreactivity). Appearance of mature KIR+ NK cells requires an additional 4–6 weeks. In this T-depleted HSCT setting, NK cells play a major role in graft-vs.-leukemia (GvL) (46). The anti-leukemia effect has been related to NK cell alloreactivity in different studies, pioneered by Ruggeri et al., in adult AML (20, 21, 45). Indeed a clear correlation was found between the frequency of alloreactive NK cells and the clinical outcome (22, 44). Of note, a subset of NK cells derived from CMV-seropositive donors could undergo expansion in transplanted patients upon CMV reactivation after HSCT. These NK cells expressed NKG2C, CD57, and displayed epigenetic modifications identical to those present in memory T cells. These characteristics confer to NK cells a strong cytolytic activity, including a “memory-like” behavior in response to NKG2C triggering, and are associated to a better clinical outcome (23–25, 47, 48). In pediatric patients receiving “megadoses” of purified CD34+, the survival probability at 5 years was very good for patients with high-risk ALL, reaching over 70% in the presence of NK alloreactivity and ~40% in its absence, the overall survival being ~60%. In patients with AML, survival reached ~40% in case of NK alloreactivity, but only ~20% in its absence, the overall survival being ~30%. Notably, all deaths occurred early, during the first few weeks/months after transplant, primarily due to leukemia relapses or infections (20, 49). In an attempt to fill the temporal gap between transplant and the generation of mature KIR+ alloreactive NK cells, a novel graft manipulation has been developed. This is based on the selective depletion of TCR αβ T cells (responsible of GvHD) and B cells (to prevent B cell malignancies in immunocompromised individuals). With this graft manipulation, the infused mononuclear cells also contain, in addition to HSC (including not only CD34+ but also CD34− precursors), effector cells such as mature (CD56dim) NK cells and TCRγδ T cells, both capable of anti-leukemia activity (12, 26, 50). In addition, the graft contained different myeloid cell types, including monocytes and low-density monocytic or polymorphonuclear (PMN) myeloid cells (51, 52). The immediate availability of cells capable of killing leukemia blasts and controlling virus reactivation or infections had a major positive impact. Indeed the overall survival probability was ~70% not only for ALL but also for AML patients. An unexpected finding was that NK cell-mediated alloreactivity did not appear to play a significant role (49). While it is conceivable that the NK cell function may be offset by a predominant GvL effect of γδT cells (greatly expanded in vivo thanks to the use of zoledronic acid) (53), we could not exclude that also other mechanisms may impair NK alloreactivity. Indeed we recently found that myeloid-derived suppressor cells (MDSC), particularly abundant in the graft, exert a potent inhibitory effect on NK cell function (54). These data suggest a possible effect also in vivo and offer a clue for applying an additional step in the graft manipulation to further remove MDSC. The rescue of NK cell function may contribute to increase the clinical outcome, particularly by preventing leukemia relapses, still representing ~25% of total deaths.

Taken together, these data support the notion that NK and other cells of the innate immunity may play a relevant role in the therapy of high-risk leukemia. Notably, HSC from different sources give rise to other innate lymphoid cells (ILC), particularly ILC3. ILC3 cells contribute to tissue repair and regeneration of lymphoid tissues and are likely to play a major role in the integrity of such tissues severely compromised by the chemo/radiotherapy given to patients prior to HSCT (55).

### BLOCKING OF INHIBITORY CHECKPOINTS/RECEPTORS TO UNLEASH NK CELLS

NK cells express inhibitory receptors such as the HLA-CI-I-specific KIRs and CD94/NKG2A that may function as true inhibitory checkpoints (56). The lack of interactions with their cognate HLA class I ligands on target cells leads to cytolytic activity and cytokine production. This may occur in an autologous environment in the case of tumors or viral infections, as well as in an allogeneic setting such as the haplo-HSCT (see above).

While KIRs and NKG2A are constitutively expressed by mature NK cells, the expression of other inhibitory checkpoints involved in the homeostasis of immune responses, including PD-1, TIGIT, TIM-3, and CD96, is inducible (57). Such
de novo-expressed checkpoint regulators have been shown to inhibit the NK cell function upon interaction with their ligands on tumor cells (19, 58). We will focus on PD-1 since it is a major checkpoint receptor involved in the control of immune responses, and the therapeutic use of blocking antibodies disrupting the PD-1/PD-L1 axis represents a major breakthrough in the cure of highly aggressive tumors.

While PD-1 expression has been first reported in T lymphocytes, recent studies revealed that, in pathological conditions, such as CMV infections and tumors, it may be expressed also by NK cells. The expression of PD-1 by NK cells is controversial; instead, PB-NK cells derived from both healthy donors (HD) and neoplastic patients were originally reported to express low levels, if any, of PD-1. On the other hand, PD-1^{bright} NK cells were found in the PB and, more abundantly, in ascitic fluid of ovarian carcinoma patients (58), as well as in pleural effusions of patients with primary and metastatic tumors (19) and in Hodgkin lymphoma. Notably, both PD-1 mRNA and PD-1 protein are present in the cytoplasm of NK cells isolated from HD (59), although the molecular mechanisms leading to its surface expression are still poorly defined.

Under physiological conditions, PD-1 acts as a brake in the regulation of immune responses, playing a relevant role in the induction and maintenance of T cell tolerance. However, in cancer patients, it may impair T cell- and NK cell-mediated responses against tumor cells. In these cases, immunotherapy with mAbs disrupting the PD-1/PD-L1 interaction has shown great effectiveness, particularly in melanoma and lung carcinomas with responses to therapy reaching 20–40% in different clinical trials. Importantly, therapeutic blockade of inhibitory checkpoints in NK cells may be effective also in HLA-CI{sup P} tumors, a condition that frequently occurs in metastatic carcinomas (as a result of tumor escape from cytolytic T cell-mediated control) (60, 61). Nevertheless, the majority of patients do not benefit from the anti-PD-1/PD-L1 treatment. Thus, prediction of clinical responses to PD-1/PD-L1 blockade represents a major issue also in view of important side effects and of the high treatment cost. In this context, an important approach is the evaluation of PD-L1 expression on tumor cells. However, its predictive value is still unsatisfactory due to several technical limitations, such as the use of different mAbs, different diagnostic materials (biopsies vs. surgical specimen, cytology), and different operators (62–64). For this reason, current researches are aimed to identify additional checkpoints to be targeted, either alone or in combination. In this context, the actual potential of blocking TIGIT, TIM-3, CD96, or LAG-3 is currently under investigation. Importantly, a recent study by Vivier’s group has highlighted the use of anti-CD94/NKG2A blocking mAb in tumor therapy (65). NKG2A{sup +} cells represent >50% of PB-NK cells and may express either the CD56{sup bright} or the CD56{sup dim} phenotype. While CD56{sup bright} NKG2A{sup +} NK cells are primarily cytokine producers, CD56{sup dim} NKG2A{sup +} cells also display potent cytolytic activity and DC editing capability (66). NKG2A is also expressed by T lymphocytes, either upon prolonged stimulation via TCR (67) or upon exposure to TGF-β (68), an immunosuppressive cytokine often present in the tumor microenvironment. This de novo NKG2A expression may lead to the impairment of T cell function, including anti-tumor activity (67). Accordingly, blocking of NKG2A can unleash not only NK cells but also tumor-infiltrating T cells with potential anti-tumor activity. In addition, HLA-E, the NKG2A ligand, is expressed in many highly aggressive tumors (e.g., lung, head and neck, colon, pancreas, and liver), and most cells in the tumor are HLA-E{sup +}. Accordingly, blocking of NKG2A may result in potent anti-tumor effect in different cancers. In tumors expressing both HLA-E and PD-L1, the combined blocking of NKG2A and PD-1/PD-L1 axis can enhance NK cell cytotoxicity and rescue T cell function. Notably, in a murine model, this combined treatment also resulted in T cell proliferation and T cell memory induction. Finally, in HLA-E{sup +} tumors, expressing tumor-associated antigens, NKG2A blockade could increase the therapeutic efficacy of other mAbs (for example, anti-EGFR mAb), favoring the NK cell triggering via the CD16-mediated antibody-dependent cytotoxicity (ADCC) (65, 69). These different scenarios involving NKG2A blockade are promising because they may occur in many tumors and involve important synergies with other checkpoint inhibitors or therapeutic antibodies directed to tumor antigens. In addition, these studies emphasize the importance of harnessing NK cell-mediated anti-tumor activity while, so far, the immunotherapeutic strategies have been mostly focused on potentiating T cell anti-tumor responses.

CONCLUDING REMARKS

It is now clear that cells of the innate immunity, in particular NK cells, play a relevant defensive role in the control of tumor growth and metastases. As shown by many experimental evidences, both in vitro and in vivo, such anti-tumor effect is related both to direct cytolytic activity and to the production of cytokines that activate other effector cells and promote useful TH1 adaptive responses. Therefore, therapeutic approaches that trigger and/or reconstitute NK cell function and proliferation are crucial in tumor immunotherapy. In addition, NK cells engineered with CAR, targeting tumor antigens, are highly promising. Indeed CAR-NK cells could complement or even replace CAR-T cells in view of their particularly potent cytolytic activity and their peculiar homing capability (70–72). Importantly, in case of loss of the targeted tumor antigen, CAR-NK cells could still exert their anti-tumor activity, particularly in the absence of KIR/HLA ligand matching. In addition, CAR-NK cells, genetically modified to over-express either molecules mediating tumor killing or cytokines able to sustain NK cell proliferation/function (e.g., IL-15), may represent a further valuable tool for adoptive cell therapy of cancer (73, 74). Notably, since NK cells do not cause GvHD, they may be obtained from unrelated donors, thus overcoming major limitations of autologous T cell therapy (time needed for preparation and high costs) and providing a rapid access to an “off-the-shelf” life-saving therapy. Indeed given the possibility to better plan treatments with standardized approaches and appropriate cell numbers, donor-derived allogeneic CAR-NK cells may represent the next generation of cell-based therapies of cancer. Table 2 summarizes recent or ongoing clinical trials based on the use of adoptively infused NK cells.
### TABLE 2 | Selected recent/ongoing trials of NK-based adoptive therapy of cancer.

| Identifier | Trial | Status | Phase | NK cells/drug | Tumor |
|------------|-------|--------|-------|---------------|-------|
| NCT00900809 | QUILT-3.018: Neukoplast™ (NK-92) for the treatment of refractory or relapsed acute myeloid leukemia | Recruitment completed | I | NK-92 | Acute myeloid leukemia |
| NCT03027128 | QUILT-3.028: study of haNK™ for infusion in subjects with metastatic or locally advanced solid tumors | Recruitment completed | I | NK-92 | Solid tumor |
| NCT03383978 | Intracranial injection of NK-92/5.28.z cells in patients with recurrent HER2-positive glioblastoma (CAR2BRAIN) | Recruiting | I | NK-92/5.28.z | Glioblastoma |
| NCT02573896 | Immunotherapy of relapsed refractory neuroblastoma with expanded NK cells | Recruiting | I | CAR-NK-Ch14.18 lenalidomide | Neuroblastoma |
| NCT02280525 | Cord blood Natural Killer (NK) cells in leukemia/lymphoma | Active, not recruiting | I | NK Cells, lenalidomide, rituximab (anti-CD20), fludarabine, cyclophosphamide, cytarabine | Leukemia |
| NCT02481934 | Clinical trial of expanded and activated autologous NK cells to treat multiple myeloma (NK-VS-MM) | Completed | I | NK Cells, lenalidomide, bortezomib | Multiple myeloma |
| NCT03415100 | Pilot study of NKG2D-ligand targeted CAR-NK cells in patients with metastatic solid tumors | Recruiting | I | CAR-NK cells targeting NKG2D ligands | Solid tumors |
| NCT01974479 | Pilot study of redirected haploidentical natural killer cell infusions for B-lineage acute lymphoblastic leukemia | Recruiting | I | Anti-CD19 redirected NK cells | B-cell acute lymphoblastic leukemia |
| NCT03579927 | CAR-CD19-CD28-zeta-2A-iCasp9-IL15-transduced cord blood NK cells, high-dose chemotherapy, and stem cell transplant in treating participants with B-cell lymphoma | Not yet recruiting | I/II | Cord blood-NK Cells, Autologous HSCT, carmustine, Cytarabine, etoposide, filgrastim, mephalan, rituximab (anti-CD20) | CD19 positive, mantle cell lymphoma, recurrent diffuse large B-cell lymphoma, recurrent follicular lymphoma, refractory B-cell non-Hodgkin lymphoma, refractory diffuse large B-Cell lymphoma, refractory follicular lymphoma |
| NCT03056339 | Umbilical and Cord Blood (CB) derived CAR-engineered NK cells for B lymphoid malignancies | Recruiting | I/II | iC9/CAR.19/IL15 transduced CB-NK Cells, fludarabine, cyclophosphamide, mesna, AP1903 | B-lymphoid malignancies, acute lymphocytic leukemia, chronic lymphocytic leukemia, non-Hodgkin lymphoma |
| NCT02839954 | CAR-pNK cell immunotherapy in MUC1 positive relapsed or refractory solid tumor | Unknown | I/II | Anti-MUC1 CAR-NK cells | Hepatocellular carcinoma, NSCLC, pancreatic carcinoma, triple-negative invasive breast carcinoma, malignant glioma of brain, colorectal carcinoma, gastric carcinoma |
| NCT02892695 | PCAR-119 bridge immunotherapy prior to stem cell transplant in treating patients with CD19 positive leukemia and lymphoma | Unknown | I/II | Anti-CD19 CAR-NK cells | Acute/chronic lymphocytic leukemia, follicular lymphoma, mantle cell lymphoma, B-cell prolymphocytic leukemia, diffuse large cell lymphoma |
| NCT02742727 | CAR-pNK cell immunotherapy in CD7 positive leukemia and lymphoma | Unknown | I/II | Anti-CD7 CAR-NK cells | Acute myeloid leukemia, precursor T-cell lymphoblastic leukemia-lymphoma, T-cell prolymphocytic leukemia, T-cell large granular lymphocytic leukemia, peripheral T-cell lymphoma, angioimmunoblastic T-cell lymphoma, extranodal NK/T-cell lymphoma, nasal type enteropathy-type intestinal T-cell lymphoma |
AUTHOR CONTRIBUTIONS

All authors wrote and revised the review.

FUNDING

Supported by grants awarded by Associazione Italiana per la Ricerca sul Cancro (AIRC)-Special Program Metastatic disease: the key unmet need in oncology 5X1000 2018 Id. 21147 (LM), AIRC IG 2017 Id. 19920 (LM); RC-2019 OPBG (LM and PV); Ministero della Salute RF-2013, GR-2013-02356568 (PV); Italian Ministry of Health Id: RF-2016-02362288 (GP); 5X1000 Italian Ministry of Health 2015 and 2016 (to MM); NT was recipient of a fellowship awarded by AIRC; RC-2019 IRCCS Ospedale Policlinico San Martino (GP).

REFERENCES

1. Moretta A, Bottino C, Vitale M, Pende D, Biassoni R, Mingari MC, et al. Receptors for HLA class-I molecules in human natural killer cells. *Ann Rev Immunol.* (1996) 14:619–48. doi: 10.1146/annurev.immunol.14.1.619
2. Moretta A, Bottino C, Vitale M, Pende D, Cantoni C, Mingari MC, et al. Activating receptors and coreceptors involved in human natural killer cell-mediated cytosis. *Ann Rev Immunol.* (2001) 19:197–223. doi: 10.1146/annurev.immunol.19.1.1197
3. Raulet DH, Vance RE. Self-tolerance of natural killer cells. *Nat Rev Immunol.* (2006) 6:520–31. doi: 10.1038/nri1863
4. Vitale M, Cantoni C, Pietra G, Mingari MC, Moretta L. Effect of tumor cells and tumor microenvironment on NK-cell function. *Eur J Immunol.* (2014) 44:1582–92. doi: 10.1002/eji.201344272
5. Vacca P, Munari E, Tumino N, Moretta F, Pietra G, Vitale M, et al. Human natural killer cells and other lymphoid cells in cancer: friends or foes? *Immunol Lett.* (2018) 201:14–9. doi: 10.1016/j.imlet.2018.11.004
6. Vitale M, Cantoni C, Della Chiesa M, Ferlazzo G, Carlomagno S, Pende D, et al. A historical overview: the discovery of how NK cells can kill enemies, recruit defense troops, and more. *Front Immunol.* (2019) 10:1415. doi: 10.3389/fimmu.2019.01145
7. Mariotti FR, Quatrini L, Munari E, Vacca P, Moretta L. Innate lymphoid cells: expression of PD-1 and other checkpoints in normal and pathological conditions. *Front Immunol.* (2019) 10:910. doi: 10.3389/fimmu.2019.00910
8. Crozatto D, Martini S, Chiossone L, Scordamaglia F, Simonassi CF, Moretta L, et al. IL15 induces a potent antitumor activity in NK cells isolated from malignant pleural effusions and overcomes the inhibitory effect of pleural fluid. *Oncoimmunology.* (2017) 6:e1293210. doi: 10.1080/2162402X.2017.1293210
9. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. *J Immunol.* (1985) 135:2865–75.
10. Levin AM, Bates DL, Ring AM, Krieg C, Lin JT, Su L, et al. Exploiting a natural conformational switch to engineer an interleukin-2 ‘superkine’. *Nature.* (2012) 484:529–33. doi: 10.1038/nature10975
11. Locatelli F, Baquet A, Palumbo G, Moretta F, Bertaina A. Negative depletion of alpha/beta+ T cells and of CD19+ B lymphocytes: a novel frontier to optimize the effect of innate immunity in HLA-mismatched hematopoietic stem cell transplantation. *Immunol Lett.* (2013) 155:21–3. doi: 10.1016/j.imlet.2013.09.027
12. Bentebibel SE, Hurwitz ME, Bernatchez C, Haymaker C, Hudgens CW, Kluger HM, et al. A first-in-human study and biomarker analysis of NKTR-214, a novel IL2Rbeta-gamma-biased cytokine, in patients with advanced or metastatic solid tumors. *Cancer Discov.* (2019) 9:711–21. doi: 10.1158/2159-8290.CD-18-1495
13. Romee R, Cooley S, Berrien-Elliot MM, Westervelt P, Verneris MR, Wagner JE, et al. First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation. *Blood.* (2018) 131:2515–27. doi: 10.1182/blood-2017-12-823757
14. Valera DA, Felices M, McElmurry R, McCullar V, Zhou X, Schmohl JU, et al. IL15 trispecific killer engagers (TriKE) make natural killer cells specific to CD33+ targets while also inducing persistence, in vivo expansion, and enhanced function. *Clin Cancer Res.* (2016) 22:3440–50. doi: 10.1158/1078-0432.CCR-15-2710
15. Thaker PH, Brady WE, Lankes HA, Odunsi K, Bradley WH, Moore KN, et al. A phase I trial of intraperitoneal GEN-1, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer, administered with pegylated liposomal doxorubicin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancers: an NRG Oncology/Gynecologic Oncology Group study. *Gynecol Oncol.* (2017) 147:283–90. doi: 10.1016/j.ygyno.2017.08.001
16. Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. *N Engl J Med.* (1985) 313:1485–92. doi: 10.1056/NEJM198512303132327
17. Rosenberg SA, Mule JJ, Spiess PJ, Reichert CM, Schwarz SL. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. *J Exp Med.* (1985) 161:1169–88. doi: 10.1084/jem.161.5.1169
18. Tumino N, Martini S, Munari E, Scordamaglia F, Besi F, Mariotti FR, et al. Presence of innate lymphoid cells in pleural effusions of primary and metastatic tumors: functional analysis and expression of PD-1 receptor. *Int J Cancer.* (2019) 145:1660–68. doi: 10.1002/ijc.32262
19. Venstrom JM, Pittari G, Gooley TA, Chewning JH, Spellman S, Haagenson M, et al. HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1. *N Engl J Med.* (2012) 367:805–16. doi: 10.1056/NEJMoa1205003
20. Savani BN, Mielke S, Adams S, Uribe M, Rezvani K, Yong AS, et al. Rapid natural killer cell recovery determines outcome after T-cell-depleted HLA-identical stem cell transplantation in patients with myeloid leukemias but not with acute lymphoblastic leukemia. *Leukemia.* (2007) 21:2145–52. doi: 10.1038/sj.leu.2404892
21. Pende D, Spaggiari GM, Marcenaro S, Martini S, Rivera P, Capobianco A, et al. Analysis of the receptor–ligand interactions in the natural killer-mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: evidence for the involvement of the poliovirus receptor (CD155) and nectin-2 (CD112). *Blood.* (2005) 105:2066–73. doi: 10.1182/blood-2004-09-3548
22. Dewald JR, Fuller DO, Muller GC, Beier JC. A novel method for mapping village-scale outdoor resting microhabitats of the primary African malaria vector, *Anopheles gambiae*. *Malar J.* (2016) 15:489. doi: 10.1186/s12936-016-1534-9
23. Cichocki F, Cooley S, Davis Z, DeFor TE, Schlums H, Zhang B, et al. CD56dimCD57+NKGC2C+ NK cell expansion is associated with reduced leukemia relapse after reduced intensity HCT. *Leukemia.* (2016) 30:456–63. doi: 10.1038/leu.2015.260
24. Cichocki F, Taras E, Chiuppesi F, Wagner JE, Blazar BR, Brunstein C, et al. Adaptive NK cell reconstitution is associated with better clinical outcomes. *JCI Insight.* (2019) 4:d125553. doi: 10.1172/jci.insight.125553
25. Li P, Malaspina D, Girolami E, Biagini S, Cucchetti E, Conflitti G, et al. Selective depletion of alpha/beta+ T cells and B cells for human leukocyte antigen-haploidentical hematopoietic stem cell transplantation. A three-year follow-up of procedure efficiency. *Biol Blood Marrow Transpl.* (2016) 22:2056–64. doi: 10.1016/j.bbmt.2016.08.006
36. Sim GC, Vitale C, Pende D, Bertaina A, Moretta F, Falco M, et al. Human natural killer cells: news in the therapy of solid tumors and high-risk leukemias. *Cancer Immunol Immunother.* (2016) 65:465–76. doi: 10.1007/s00262-015-1744-y

28. Vacca P, Martini S, Garelli V, Passalacqua G, Moretta L, Mingari MC. NK cells from malignant pleural effusions are not anergic but produce cytokines and display strong antitumor activity on short-term IL-2 activation. *Eur J Immunol.* (2013) 43:591–60. doi: 10.1002/eji.201242783

29. Vacca P, Martini S, Mingari MC, Moretta L. NK cells from malignant pleural effusions are potent antitumor effectors: a clue for adoptive immunotherapy? *Oncoimmunology.* (2013) 2:e223638. doi: 10.4161/enc.223638

30. Terme M, Ulrich E, Delahaye NF, Chaput N, Zitvogel L. Natural killer cell-directed therapies: moving from unexpected results to successful strategies. *Nat Immunol.* (2008) 9:486–94. doi: 10.1038/ni.1580

31. Terme M, Fridman WH, Tartour E. NK cells from pleural effusions are potent antitumor effector cells. *Eur J Immunol.* (2013) 43:3331–4. doi: 10.1002/eji.201243264

32. Ni I, Miller M, Stojschanov A, Garbi N, Cerwenka A. Sustained effector function of IL-12/15/18-activated NK cells against established tumors. *J Exp Med.* (2012) 209:2351–65. doi: 10.1084/jem.201209944

33. Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 259 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. *J Clin Oncol.* (1995) 13:688–96. doi: 10.1092/10.1002/jco.100133.63.688

34. Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. *J Clin Oncol.* (1999) 17:2105–16. doi: 10.1200/JCO.1999.17.7.2105

35. Rosenzweig SA. IL-2: the first effective immunotherapy for human cancer. *J Immunol.* (2014) 192:5451–8. doi: 10.4049/jimmunol.1400019

36. Sim GC, Liu C, Wang E, Liu H, Creasy C, Dai Z, et al. IL2 variant circumvents IL-2 receptor expressions on cancer cells to induce antitumor activity in murine models. *J Immunol.* (2016) 196:983–94. doi: 10.1155/10.1002/jem.20160666.CIR-15-0195

37. Carmenate T, Pacios A, Enamorado M, Moreno E, Garcia-Martinez K, Fuente D, et al. Human IL-2 mulein with higher antitumor efficacy than wild type IL-2. *J Immunol.* (2013) 190:6230–8. doi: 10.1200/JCO.2013.41.10.001111

38. Cooley S, He F, Bachanova V, Vercellotti GM, DeFor TE, Curtissinger JM, et al. First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia. *Blood Adv.* (2019) 3:1970–80. doi: 10.1182/bloodadvances.2018028332

39. Wrangle JM, Velchti V, Patel MR, Garrett-Mayer E, Hill EG, Ravenel JG, et al. ALT-803, an IL-15 superagonist, in combination with etanercept in patients with metastatic non-small cell lung cancer: a phase 1b trial. *Lancet Oncol.* (2018) 19:694–704. doi: 10.1016/S1470-2045(18)30148-7

40. Sarhan D, Brandt L, Felices M, Guileveld K, Lenvik T, Aptsiauri N, et al. Identification of a subset of human natural killer cells expressing high levels of programmed death 1: a phenotypic and functional characterization. *Eur J Immunol.* (2013) 43:588–98. doi: 10.1002/eji.201546079

41. Davis ZB, Vallera DA, Miller JS, Felices M. Natural killer cells unleashed: Cellular players of hematopoietic stem cell mobilization in the bone marrow niche. *Int J Hematol.* (2017) 105:129–40. doi: 10.1007/s10537-017-6353-1

42. Gragert L, Eapen M, Williams E, Freeman J, Spellman S, Baitty R, et al. HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry. *Thorac Oncol.* (2018) 13:1113–20. doi: 10.1016/j.jto.2018.04.017

43. Rocha V, Locatelli F. Searching for alternative hematopoietic stem cell mobilization criteria for harmonization between biopsy specimens and whole sections. *J Thorac Oncol.* (2018) 13:1113–20. doi: 10.1016/j.jto.2018.04.017

44. Muccio L, Falco M, Lenzini L, Marconi M, Sommaggio M, et al. Phenotypic and functional heterogeneity of human NK cells developing after umbilical cord blood transplantation: a role for human cytomegalovirus? *Blood.* (2012) 119:399–410. doi: 10.1182/blood-2011-08-372003

45. Ruggeri L, Capanni M, Urbani E, Perruccio K, Slomchik WD, Tosti A, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. *Science.* (2002) 295:2097–100. doi: 10.1126/science.1068440

46. Falco M, Pende D, Munari E, Vacca P, Mingari MC, Moretta L. Natural killer cells: from surface receptors to the cure of high-risk leukemia (Ceppellini Lecture). *HLA.* (2019) 93:185–94. doi: 10.1111/tan.13509

47. Ruggeri L, Falco M, Bertaina A, Locatelli F, Frassoni F, Sivori S, et al. Late development of FcεRIγama(neg) adaptive natural killer cells upon human cytomegalovirus reactivation in umbilical cord blood transplantation recipients. *Front Immunol.* (2018) 9:1050. doi: 10.3389/fimmu.2018.01050

48. Moretta L, Moretta A, Frassoni F, Sivori S, et al. Phenotypic and functional heterogeneity of human NK cells developing after umbilical cord blood transplantation: a role for human cytomegalovirus? *Blood.* (2012) 119:399–410. doi: 10.1182/blood-2011-08-372003

49. Locatelli F, Merli P, Pagliara D, Li Pira G, Falco M, Pende D, et al. Outcome of children with acute leukemia given HLA-haploidentical HSCT after alphabeta T-cell and B-cell depletion. *Blood.* (2017) 130:677–85. doi: 10.1182/blood-2017-04-79769
64. Munari E, Zamboni G, Lunardi G, Marconi M, Brunelli M, Martignoni G, et al. PD-L1 expression in non-small cell lung cancer: evaluation of the diagnostic accuracy of a laboratory developed test using clone E1L3N in comparison with 22C3 and SP263 assays. *Hum Pathol.* (2019) 90:54–59. doi: 10.1016/j.humpath.2019.05.003

65. Andre P, Denis C, Soulas C, Bourbon-Caillet C, Lopez J, Arnoux T, et al. Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells. *Cell.* (2018) 175:1731–43.e13. doi: 10.1016/j.cell.2018.10.014

66. Della Chiesa M, Vitale M, Carlomagno S, Ferlazzo G, Moretta L, Moretta A. The natural killer cell-mediated killing of autologous dendritic cells is confined to a cell subset expressing CD94/NKG2A, but lacking inhibitory killer Ig-like receptors. *Eur J Immunol.* (2003) 33:1657–66. doi: 10.1002/eji.200323986

67. Mingari MC, Ponte M, Bertone S, Schiavetti F, Vitale C, Bellomo R, et al. HLA class I-specific inhibitory receptors in human T lymphocytes: interleukin 15-induced expression of CD94/NKG2A in superantigen- or alloantigen-activated CD8+ T cells. *Proc Natl Acad Sci USA.* (1998) 95:1172–7. doi: 10.1073/pnas.95.3.1172

68. Bertone S, Schiavetti F, Bellomo R, Vitale C, Ponte M, Moretta L, et al. Transforming growth factor-beta-induced expression of CD94/NKG2A inhibitory receptors in human T lymphocytes. *Eur J Immunol.* (1999) 29:23–9. doi: 10.1002/(SICI)1521-4141(199901)29:01<23::AID-IMMU23>3.0.CO;2-Y

69. Mingari MC, Pietra G, Moretta L. Immune checkpoint inhibitors: anti-NKG2A antibodies on board. *Trends Immunol.* (2019) 40:83–5. doi: 10.1016/j.it.2018.12.009

70. Ingegnere T, Mariotti FR, Pelosi A, Quintarelli C, De Angelis B, Tumino N, et al. Human CAR NK cells: a new non-viral method allowing high efficient transfection and strong tumor cell killing. *Front Immunol.* (2019) 10:957. doi: 10.3389/fimmu.2019.00957

71. Daher M, Rezvani K. Next generation natural killer cells for cancer immunotherapy: the promise of genetic engineering. *Carr Opin Immunol.* (2018) 51:146–53. doi: 10.1016/j.coi.2018.03.013

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The handling editor declared a shared affiliation, though no other collaboration, with the authors PV, NT, and LM.

Copyright © 2020 Vacca, Pietra, Tumino, Munari, Mingari and Moretta. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.